CDK4 and Miyoshi myopathy: Herein, we report on the potential of cyclin-dependent kinase 4 (CDK4) inhibitors as molecular targeted therapies for MM.<h4>Study design</h4>Retrospective cohort study and laboratory analysis.<h4>Setting</h4>A tertiary referral center.<h4>Methods</h4>MTT assay and western blotting were performed on the HMV-II (RCB0777) and GAK (JCRB0180) cell lines, treated with the CDK4 inhibitors abemaciclib (LY2835219) and palbociclib (PD-0332991).